Connection of publications with planned research works.This work is a fragment of the research programmes of the National University of Pharmacy "Pharmacological Study of Biologically Active Substances and Medicinal Products", state registration number 0114U000956, and "Cellular and Molecular Mechanisms of Development and Correction of Pathological Conditions", state registration number 0115U000966.Introduction.Pathology of the endocrine system occupies a leading position in the structure of the total morbidity of the population. In recent years, the level of endocrinological diseases has tended to increase both worldwide and, in our country [1-2]. There is an increase in the number of patients with various endocrinopathies, one of the most common of which is thyroid disease. Increased interest in the problems of thyroid pathology in Ukraine in recent years has been caused by its growing prevalence among the adult population, high incidence of temporary and permanent disability [3][4]. Thyroid pathology accounts for 46% of the total endocrinological morbidity, given the fact that thyroid diseases include I-III-degree goiter (18.6%), nodular goiter (9.8%), hypothyroidism (6.4%), thyroiditis (5.9%), thyrotoxicosis (1.7%) and thyroid cancer (4,3%) [5][6][7].Disruption of the functional activity of the thyroid gland leads to changes in metabolic processes and, as a result, imbalances in the homeostasis system. A special role in ensuring adaptation is played by hormones synthesized by the thyroid gland -thyroxine and triiodothyronine, which affect a wide range of metabolic and physiological processes. The effects of thyroid hormones on the cardiovascular system are well studied. Thyroid hormones regulate the processes of systolic contraction and diastolic relaxation of the heart muscle, overall peripheral vascular resistance, and the synthesis of myocardial structural proteins. Thyroid hormones regulate the activity of the apoB receptor in hepatocytes by genomic and non-genomic means, thus affecting the catabolism of atherogenic low-density lipoproteins. In the ORCID and contributionship: Kononenko A. H.: https://orcid.org/0000-0002-2132-7702 ABCD Kravchenko V. M.: https://orcid.org/0000-0001-6335-2490 FE